SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (鈥淛unshi Biosciences,鈥 HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company鈥檚 anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (鈥淓S-SCLC鈥?, has been accepted for review by the National Medical Products Administration (鈥淣MPA鈥?.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed